In the era of neoadjuvant chemotherapy, how reliable is biopsy for assessment of LVI to make decisions about PMRT?
Is there often discordance with LVI status in biopsy vs. mastectomy such that biopsy resulting as LVI negative is not reliable to decide on PMRT indications? Is reliability of LVI on biopsy subject to pathology techniques or is it a sampling issue?
Answer from: Radiation Oncologist at Community Practice
If bx is negative for LVI and final path is negative after NACT, then would not speculate about the possibility of LVI as risk factor for PMRT decisions.